Artificial Intelligence
Global Cell Based Assay & High Content Screening Markets Report 2021-2025 with Profiles of Key Cell Based Assay Companies
Dublin, Feb. 22, 2021 (GLOBE NEWSWIRE) — The “Cell Based Assay & High Content Screening Markets. Market Forecasts by Application with Executive and Consultant Guides and including Customized Forecasting and Analysis. 2021 to 2025” report has been added to ResearchAndMarkets.com’s offering.
Cell-Based Assays are a mainstay of drug development and scientific research, but growth is now accelerating as the race for a COVID-19 cure gains speed.
On top of this, new technology is allowing Cell-Based Assays to be used to measure any aspect of cell function. This market just keeps on growing with no end in sight. The workhorse of the pharmaceutical industry is becoming a central player in biotechnology.
This is a complex area but this readable report will bring the entire management team up to speed, on both the technology and the opportunity.
The technology is moving faster than the market. Genomics and Immunology are playing a role too. Find the opportunities and pitfalls. Understand growth expectations and the ultimate potential market size.
Key Topics Covered:
Market Guides
- Situation Analysis & COVID-19 Impact
- Guide for Executives and Marketing Staff
- Guide for Investment Analysts and Management Consultants
1. Introduction and Market Definition
1.1 What are Cell Based Assays?
1.2 Clinical Trial Failures
1.2.1 Immuno-oncology Plays a Leading Role in Cell Based Assays
1.2.2 Infectious Disease Will Play a Larger Role
1.3 Market Definition
1.3.1 Market Size
1.3.2 Currency
1.3.3 Years
1.4 Methodology
1.4.1 Authors
1.4.2 Sources
1.5 U.S. Medical Market and Pharmceutical Research Spending – Perspective
1.5.1 U.S. Expenditures for Pharmaceutical Research
2. Cell Based Assays – Guide to Technology
2.1 Cell Cultures
2.1.1 Cell Lines
2.1.2 Primary Cells
2.1.3 Stem Cells
2.1.3.1 iPSC’s – The Special Case
2.2 Cell Assays
2.3 Cell Viability Assays
2.3 Cell Proliferation Assays
2.4 Cytotoxicity Assays
2.5 Cell Senescence Assays
2.6 Apoptosis
2.7 Autophagy
2.8 Necrosis
2.9 Oxidative Stress
2.10 2D vs. 3D
2.11 Signalling Pathways, GPCR
2.12 Immune Regulation & Inhibition
2.13 Reporter Gene Technology
2.14 CBA Design & Development
2.15 Cell Based Assays – The Takeaway
3. Industry Overview
3.1 Players in a Dynamic Market
3.1.1 Academic Research Lab
3.1.2 Contract Research Organization
3.1.3 Genomic Instrumentation Supplier
3.1.5 Cell Line and Reagent Supplier
3.1.6 Pharmaceutical Company
3.1.7 Audit Body
3.1.8 Certification Body
4. Market Trends
4.1 Factors Driving Growth
4.1.1 Candidate Growth
4.1.2 Immuno-oncology
4.1.3 Genomic Blizzard
4.1.4 Technology Convergence
4.1.5 The Insurance Effect
4.2 Factors Limiting Growth
4.2.1 CBA Development Challenges
4.2.2 Instrument Integration
4.2.3 Protocols
4.3 Technology Development
4.3.1 3D Assays
4.3.2 Automation
4.3.3 Software
4.3.4 Primary Cells
4.3.5 Signalling and Reporter Genes
4.3.6 The Next Five Years
5. Cell Based Assays Recent Developments
5.1 Recent Developments – Importance and How to Use This Section
5.1.1 Importance of These Developments
5.1.2 How to Use This Section
- Axxam and FUJIFILM Cellular Dynamics Announce Strategic Alliance
- Cancer Genetics to Acquire Organoid Startup Stemonix
- Curi Bio Acquires Artificial Intelligence Firm Dana Solutions
- CRISPR Screens Uncover Novel Cancer Therapy Targets
- ERS Genomics Licenses CRISPR-Cas9 Patents to Axxam
- New Transcriptomics Assay Facilitates Compound Screens
- Carta Biosciences Betting on Gene Interaction Mapping
- High-throughput Identifies cancer drug candidates
- Velabs Therapeutics partners with Alytas Therapeutics to develop a novel immune-based therapy for obesity
- InSphero platform selected to test Cyclerion’s sGC stimulator technology
- OcellO to provide in vitro research services to Merus
- Charles River Laboratories to acquire Citoxlab
- Reaction Biology Corporation Purchases ProQinase GmbH
- Cisbio extends its assay portfolio for immuno-oncology drug discovery
- STEMCELL Technologies Launches Next-Generation Culture System
- Abcam Acquires Calico Biolabs
- Evotec announces achievement in Celgene alliance utilizing IPSC
- screening
- Fujifilm Cellular Dynamics Inc. launches iCELL Microglia
- Cisbio and Excellerate Bioscience partner
- Horizon Discovery extends CRISPR Screening Service to primary human T cells
6. Profiles of Key Cell Based Assay Companies
- Abcam
- Agilent
- Aurora Instruments Ltd
- Axxam
- Beckman Coulter Diagnostics
- Becton, Dickinson and Company
- BioIVT
- Bio-Rad Laboratories, Inc.
- BioTek Instruments
- BioVision, Inc.
- BMG Labtech
- Cell Biolabs, Inc
- Cell Signaling Technology, Inc.
- Charles River Laboratories
- Cisbio Bioassays
- Corning, Inc
- Cytovale
- Enzo Life Sciences, Inc
- Eurofins DiscoverX Corporation
- Evotec AG
- Excellerate Bioscience
- Fujifilm Cellular Dynamics International
- Genedata
- Hemogenix
- Horizon Discovery
- Invivogen
- Leica Biosystems
- Lonza Group Ltd.
- Luminex Corp
- Merck & Co., Inc
- Miltenyi Biotec
- Molecular Devices
- Nanion
- Ncardia
- New England Biolabs, Inc
- Olympus
- Origene Technologies
- Perkin Elmer
- Promega
- Qiagen Gmbh
- Reaction Biology
- Recursion Pharma
- Roche Diagnostics
- Sartorius
- Sartorius-ForteBio
- Sartorius-IntelliCyt
- Sony Biotechnology
- SPT Labtech
- Stemcells Technologies Canada Inc
- Tecan
- Thermo Fisher Scientific Inc.
- Vitro Biopharma
7. Global Market Size
7.1 Global Market Overview by Country
7.2 Global Market by User – Overview
7.3 Global Market by Product Class – Overview
8. Global Market by User Type
8.1 Pharma
8.2 Research
8.3 Industry/Cosmetic
9. Cell Based Assay by Product Class
9.1 Instrument
9.2 Reagent
9.3 Services
9.4 Software
10. Appendices
10.1 FDA Cancer Drug Approvals by Year
10.2 Clinical Trials Started 2010 to 2016
10.3 Share of Pharma R&D by Country
For more information about this report visit https://www.researchandmarkets.com/r/klj3ld
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Artificial Intelligence
XtalPi Unveils XtalGazer: A Comprehensive AI-Driven Polymorph Selection Platform
CAMBRIDGE, Mass., March 28, 2024 /PRNewswire/ — XtalPi Inc., a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the discovery of groundbreaking medicine and innovative materials, announced today the launch of its proprietary comprehensive solid form discovery and selection platform, XtalGazer. This advanced platform aims to significantly improve the polymorph selection process for the pharmaceutical industry by integrating AI- and automation-powered experimental and computational approaches.
XtalGazer provides a total solution for delivering high-quality polymorph screening and selection methods to expedite drug development and mitigate risks. It represents a paradigm shift in solid-state research, moving from the traditional trial-and-error approach to a data-driven, design-led methodology. The platform provides an expansive suite of foundational tools to accelerate polymorph discovery, characterization, and selection process, empowering pharmaceutical companies to conduct thorough research with less active pharmaceutical ingredient (API) in shorter development cycles.
A key component of XtalGazer is XtalCSP, a crystal structure prediction platform to perform global searches of crystal structures for target molecules and the other optional components in the corresponding searching space, offering a deep insight into possible stable forms. Furthermore, crystallization strategy recommendations will provide AI-backed experimental design to help avoid human bias. XtalGazer also utilizes MicroED to rapidly elucidate crystal structures from powder samples, reducing the need for growing single crystals.
XtalPi’s launch of XtalGazer marks another significant step in the company’s ongoing exploration of solid-state research. From crystal structure prediction platforms being one of the first products to launch at XtalPi, to today’s comprehensive polymorph selection platform, XtalPi will keep fulfilling its promise to solving challenging problems in this space. XtalPi will continue to deliver faster, more accurate, and more comprehensive approaches to building an ecosystem for the R&D process in solid-state, pre-formulation and crystallization.
For more information about XtalPi, please visit www.xtalpi.com.
About XtalPi:
XtalPi is an innovative technology company powered by artificial intelligence (AI) and robotics. Founded in 2015 on the MIT campus, XtalPi is dedicated to driving intelligent and digital transformation in the life science and new materials industries. With tightly interwoven quantum physics, AI, cloud computing, and large-scale clusters of robotic workstations, XtalPi offers a range of technology solutions, services, and products to accelerate and empower innovation for biopharmaceutical and new materials companies worldwide.
Media Contact: Vivienne [email protected]
Logo – https://mma.prnewswire.com/media/632519/XtalPi_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/xtalpi-unveils-xtalgazer-a-comprehensive-ai-driven-polymorph-selection-platform-302102794.html
Artificial Intelligence
ICIS and Base Oil News Announce Partnership to Enhance Market Insights
LONDON, March 28, 2024 /PRNewswire/ — ICIS, a global source of commodity intelligence, is pleased to announce a strategic partnership with Base Oil News, a premier news outlet founded by industry expert Iain Pocock that provides in-depth coverage of the base oils and lubricants market. This collaboration marks a significant milestone in the dissemination and exchange of critical market data and insights.
With more than two decades of journalism experience at Bloomberg, Reuters, and Argus Media, Iain Pocock brings unparalleled expertise to this partnership. His deep understanding of illiquid energy markets makes him a credible and influential figure in the industry. Since November 2023, Iain has been working closely with ICIS to share and exchange valuable data and insights, enhancing the services both platforms offer to the base oils and lubricants market.
Through the collaboration, Iain integrates ICIS’ extensive content and data resources in Base Oil News market coverage. In return, he contributes market insights to ICIS News, including expert and exclusive analysis of supply and demand dynamics, price margins, and other critical market drivers. This exchange ensures that subscribers of both ICIS and Base Oil News have access to the most comprehensive, timely, and accurate market information, empowering them to make informed decisions.
“It’s a very exciting partnership – where we leverage each other’s strengths and provide actionable insights to our customers,” said Iain Pocock, Founder of Base Oil News. “The market is the winner.”
“As ICIS is already the world’s most trusted pricing benchmark for base oils, this collaboration with Iain Pocock and Base Oil News provides an even stronger and deeper service to our customers,” said Stephen Burns, Editorial Director at ICIS. “Iain’s expertise and extensive industry connections are invaluable, and we have established a fruitful partnership that benefits the market at large.”
For the latest insights from Iain Pocock on ICIS News, visit ICIS News.
About ICIS
ICIS – Independent Commodity Intelligence Services – helps businesses through seamlessly delivering data and analytics, across the chemical, fertilizer and energy markets. A trusted source and benchmark for price information and insight across key commodities markets worldwide. Our independent, transparent market intelligence informs thousands of quality decisions every day, taking the pressure out of negotiations and giving customers space for more innovative thinking, through published datasets including price assessments, price forecasts, supply and demand fundamentals and more.
Over 150 years of shaping the world by connecting markets to optimise the world’s valuable resources. With a global team of more than 600 experts, ICIS has employees based in London, New York, Houston, Karlsruhe, Milan, Mumbai, Singapore, Guangzhou, Beijing, Shanghai, Dubai, Sao Paulo, Seoul, Tokyo and Perth.
ICIS is part of RELX, a FTSE15 company with a market cap of £64bn and an employee base of over 30,000 experts across 40 countries.
About RELX
RELX is a global provider of information and analytics for professional and business customers across industries. The Group serves customers in more than 180 countries and has offices in about 40 countries. It employs approximately 30,000 people of whom almost half are in North America. RELX PLC is a London listed holding company which owns 52.9% of RELX Group. RELX NV is an Amsterdam listed holding company which owns 47.1% of RELX Group. The shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX and RENX. Total market capitalisation is approximately £64bn | €75bn | $81bn.
Logo: https://mma.prnewswire.com/media/619935/4277787/ICIS_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/icis-and-base-oil-news-announce-partnership-to-enhance-market-insights-302102782.html
Artificial Intelligence
Trianz Welcomes Israel Abraham as Vice President of Services for Extrica.ai – The Data to AI Platform
SANTA CLARA, Calif., March 28, 2024 /PRNewswire/ — Digital transformation technology & services company Trianz is pleased to announce the appointment of Israel Abraham as Vice President of Extrica Platform Services.
Trianz has embarked on a transformative journey, redefining its value proposition with an ‘IP Led’ model, with a commitment to deliver the fastest time to value, lowest human dependence, and highest ROI. Central to this approach are our hyper-automated platforms, Concierto.Cloud, Extrica.AI, and Pulse, driving industry-leading transformations in cloud, data and analytics, AI, and the digital workplace.
Israel Abraham is a very well-known pioneer and industry leader in AI, data management, and analytics systems, with over three decades of experience. He joins as the services leader for Extrica- the Trianz Data to AI platform, which productizes data, provides data a face and purpose, and accelerates time to insights and AI by 50% or more. In the role of Extrica Services leader, Israel will lead the shaping, visioning, and delivery of Extrica.ai based enterprise wide datamesh, BI, and AI solutions for customers worldwide.
“We are thrilled to welcome Israel Abraham to the Trianz family,” said Sri Manchala, CEO of Trianz and author of Crossing the Digital Faultline. “He is a leader in modernization as well as conceptualization of data platforms anew. Israel’s prior background in the industry with financial services and insurance giants underscores our commitment to securing top-tier talent that brings real-world experiences and needs to our technology platforms. As we continue to broaden our footprint in the digital transformation space, Israel’s visionary leadership and practical experience will serve as the cornerstone in accelerating insights and AI to deliver transformative value to our clients.”
Having played pivotal roles in highly reputed and large organizations such as Liberty Mutual Insurance, MassMutual, Safeco, and CNA Insurance, Israel has garnered recognition as a seasoned leader in big data and AI cloud implementations. His accolades include the prestigious 2014 Ventana Research IT Innovation Award, the 2009 Informatica MDM Innovation Award, and three filed Data Engineering patents in the last four years.
“Trianz has been at the forefront of digital innovation, and Extrica.ai is a paradigm shifting data to AI platform that completely changes how analytics and AI are delivered- much faster, taking business ahead of change. I am excited to scale the adoption of the Extrica platform, which has attracted attention from giants across the industry and hyperscalers,” said Israel Abraham. “I look forward to engaging with customers, bringing my own experiences, and collaborating with the talented team at Trianz to further enhance the capabilities of the Extrica Platform Services to transform data & AI strategies, execution, and outcomes for customers.”
About Trianz
Trianz is a leading-edge technology platforms and services company that accelerates digital transformations at Fortune 100 and emerging companies worldwide in data & analytics, digital experiences, cloud infrastructure, and security. Our ‘IP Led Transformations’ approach, informed by insights from a recent global study spanning 20+ industries and 5000+ companies, addresses challenges posed by the rapid pace of AI-driven transformation, digital talent scarcity, and economic uncertainty. Our IP and platforms, including Concierto, Extrica, and Pulse, revolutionize cloud adoption, data analytics, and AI insights, empowering organizations to navigate the complexities of digital transformation seamlessly.
Founded in California and with an organization of over 2,000 associates across the United States and India, Trianz is a Premier Partner of AWS, consistently rated #1 by clients for value delivery over the past five years. Trianz has been ranked as one of the best Consulting Firms by Forbes and has been certified as a Great Place to Work for three years in a row. To learn more about Trianz, email [email protected] or visit www.trianz.com.
Watch Trianz CEO Sri Manchala’s insightful interview with Bloomberg on Partner | Crossing The Digital Faultline & Leading Towards Transformative Success – YouTube and delve deeper into his book Crossing the Digital Faultline at Crossing the Digital Faultline | Trianz.
Trianz Media [email protected] +1-408-387-5800
Logo: https://mma.prnewswire.com/media/626944/1199800/Trianz_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/trianz-welcomes-israel-abraham-as-vice-president-of-services-for-extricaai–the-data-to-ai-platform-302102589.html
-
Artificial Intelligence7 days ago
Document Collaboration Hub (DCH) by Netcare International Now Available on Microsoft AppSource
-
Artificial Intelligence6 days ago
Smartkem Commences Project with RiTdisplay To Develop World’s First Commercially Ready Active-Matrix OLED Display Using OTFT Technology
-
Artificial Intelligence6 days ago
Hexaware Dominates Whitelane Research 2024 BeLux IT Sourcing Study: A Triumph in Continued CSAT Excellence
-
Artificial Intelligence6 days ago
Wine of Moldova offers a glimpse of the future with its game-changing AI tool
-
Artificial Intelligence6 days ago
World System Integrator Conference (WSIC) 2024 A Showcase of New Initiatives
-
Artificial Intelligence6 days ago
Disaster Preparedness Systems Market Projected to Reach $300.20 billion by 2030 – Exclusive Report by 360iResearch
-
Artificial Intelligence6 days ago
Decision Intelligence Market worth $50.1 billion by 2030 – Exclusive Report by MarketsandMarkets™
-
Artificial Intelligence6 days ago
YASH Technologies Partners with Baheya Foundation to Transform Cancer Care in Egypt